P. Noble, C. Albera, W. Bradford, U. Costabel, M. Glassberg et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, The Lancet, vol.377, issue.9779, pp.1760-176905, 2011.
DOI : 10.1016/S0140-6736(11)60405-4

URL : https://hal.archives-ouvertes.fr/hal-00873255

A. Fischer and R. Bois, Interstitial lung disease in connective tissue disorders, The Lancet, vol.380, issue.9842, pp.689-698
DOI : 10.1016/S0140-6736(12)61079-4

A. Peljto, M. Steele, T. Fingerlin, M. Hinchcliff, E. Murphy et al., The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis, Chest, vol.142, issue.6, p.5, 2012.
DOI : 10.1378/chest.12-0110

A. Andersson-sjoland, K. Nihlberg, L. Eriksson, L. Bjermer, and G. Westergren-thorsson, Fibrocytes and the tissue niche in lung repair, Respiratory Research, vol.8, issue.1, p.76, 2011.
DOI : 10.1096/fj.05-4682rev

P. Noble, C. Barkauskas, and D. Jiang, Pulmonary fibrosis: patterns and perpetrators, Journal of Clinical Investigation, vol.122, issue.8, pp.2756-62
DOI : 10.1172/JCI60323

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408732

S. Marchand-adam, A. Fabre, A. Mailleux, J. Marchal, C. Quesnel et al., Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.1, pp.58-6601, 2006.
DOI : 10.1164/rccm.200507-1074OC

T. King, . Jr, A. Pardo, and M. Selman, Idiopathic pulmonary fibrosis, The Lancet, vol.378, issue.9807, pp.1949-6102, 2011.
DOI : 10.1016/S0140-6736(11)60052-4

URL : https://hal.archives-ouvertes.fr/hal-00873255

C. Robinson, R. Neary, A. Levendale, C. Watson, and J. Baugh, Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype, Respiratory Research, vol.13, issue.1, p.74, 2012.
DOI : 10.1016/S0002-9440(10)63330-5

K. Pandit, J. Milosevic, and N. Kaminski, MicroRNAs in idiopathic pulmonary fibrosis, Translational Res J Lab Clin Med, vol.15723, issue.4, pp.191-200, 2011.

G. Lindahl, C. Stock, X. Shi-we, P. Leoni-garcia, P. Sestini et al., Microarray profile reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease, Respir Res, 2013.

B. Higgs, Z. Liu, B. White, W. Zhu, W. White et al., Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway, Annals of the Rheumatic Diseases, vol.70, issue.11
DOI : 10.1136/ard.2011.150326

A. Grassegger, G. Schuler, G. Hessenberger, B. Walder-hantich, J. Jabkowski et al., Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial, British Journal of Dermatology, vol.38, issue.9, pp.639-687, 1998.
DOI : 10.1006/clin.1996.0118

G. Raghu, C. Bozic, K. Brown, D. Lynch, D. Center et al., Feasibility of a trial of interferon-beta1A in the treatment of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.163, p.707, 2001.

T. King, . Jr, C. Albera, W. Bradford, U. Costabel et al., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial, The Lancet, vol.374, issue.9685, pp.222-80703, 2009.
DOI : 10.1016/S0140-6736(09)60551-1

K. Diaz, S. Skaria, K. Harris, M. Solomita, S. Lau et al., Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis, J Aerosol Med Pulm Drug Deliv, vol.2012, issue.252, pp.79-87

W. Soon, M. Hariharan, and M. Snyder, High-throughput sequencing for biology and medicine, Molecular Systems Biology, vol.759, issue.1, p.640
DOI : 10.1038/ng1891